primaquine phosphate

CLINICAL USE

Treatment of malaria ( Plasmodium vivax and Plasmodium ovale), in combination with chloroquineTreatment of Pneumocystis jiroveci pneumonia (PCP), in combination with clindamycin

DOSE IN NORMAL RENAL FUNCTION

Malaria: 15–30 mg once daily for 14 days PCP: 30 mg once daily

PHARMACOKINETICS

Molecular weight :455.3

%Protein binding :No data

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :3–4

half-life – normal/ESRD (hrs) :3–6/Unknown

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antimalarials: avoid concomitant use with artemether/lumefantrine

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Primaquine base 7.5 mg is approximately equivalent to 13.2 mg primaquine phosphateMajor metabolite, 8-(3-carboxyl-1- methylpropylamino)-6-methoxyquinolone, possesses less antimalarial activity than the parent compound

Contraindicated in acutely ill patients with rheumatoid arthritis or SLE – increased risk of developing granulocytopeniaRisk of haemolytic anaemia in patients with G-6-PD deficiency; haemolysis generally appears 2–3 days after primaquine administration. Risk of methaemoglobinaemia at high doses

Tags: post-by-auto-php